Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 63, Issue 3, 2004, Pages 274-279

  Van Aken, J ^a   Lard, L R ^a   Le Cessie, S ^a   Hazes, J M W ^b   Breedveld, F C ^a   Huizinga, T W J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIRHEUMATIC AGENT; CHLOROQUINE; EPITOPE; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; GENETIC PREDISPOSITION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOGRAPHY; RHEUMATOID ARTHRITIS; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHLOROQUINE; DISEASE PROGRESSION; EPITOPES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HLA-DR ANTIGENS; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; RHEUMATOID FACTOR; SULFASALAZINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 1342343999     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.010298     Document Type: Article

References (33)

1. Pincus T, Callahan LF. What is the natural history of rheumatoid arthritis? Rheum Dis Clin North Am 1993;19:123-51.
2. Scott DL, Symmons DP, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987;1:1108-11.
3. van Zeben D, Hazes JM, Zwinderman AH, Vandenbroucke JP, Breedveld FC. The severity of rheumatoid arthritis: a 6-year followup study of younger women with symptoms of recent onset. J Rheumatol 1994;21:1620-5.
4. Pincus T. Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 1988;41:1037-41.
5. Furst DE. Rational use of disease-modifying antirheumatic drugs. Drugs 1990;39:19-37.
6. Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994;330:1368-75.
7. Huizinga TW, Machold KP, Breedveld FC, Lipsky PE, Smolen JS. Criteria for early rheumatoid arthritis: from Bayes' law revisited to new thoughts on pathogenesis. Arthritis Rheum 2002;46:1552-9.
8. Hannonen P, Mottonen T, Hakola M, Oka M. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1993;36:1501-9.
9. Lard LR, Visser H, Speyer I, vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001;111:446-51.
10. van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, Booma-Frankfort C, van der Veen MJ, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996;124:699-707.
11. Borg G, Allander E, Lund B, Berg E, Brodin U, Pettersson H, et al. Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind, placebo controlled study. J Rheumatol 1988;15:1747-54.
12. Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995;22:2208-13.
13. Mottonen T, Paimela L, Ahonen J, Helve T, Hannonen P, Leirisalo-Repo M. Outcome in patients with early rheumatoid arthritis treated according to the "sawtooth" strategy. Arthritis Rheum 1996;39:996-1005.
14. van Zeben D, Hazes JM, Zwinderman AH, Cats A, Schreuder GM, D'Amaro J, et al. Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a followup study. Arthritis Rheum 1991;34:822-30.
15. Emery P, Salmon M, Bradley H, Wordsworth P, Tunn E, Bacon PA, et al. Genetically determined factors as predictors of radiological change in patients with early symmetrical arthritis. BMJ 1992;305:1387-9.
16. van der Heijde DM, van Riel PL, van Leeuwen MA, van't Hof MA, van Rijswijk MH, van de Putte LB. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 1992;31:519-25.
17. Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992;117:801-6.
18. Lard LR, Boers M, Verhoeven A, Vos K, Visser H, Hazes JM, et al. Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis Rheum 2002;46:899-905.
19. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
21. van der Heijde DM. Plain X-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol 1996;10:435-53.
22. Visser H, Gelinck LB, Kampfraath AH, Breedveld FC, Hazes JM. Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assays in rheumatoid arthritis. Ann Rheum Dis 1996;55:157-61.
23. O'Dell JR, Nepom BS, Haire C, Gersuk VH, Gaur L, Moore GF, et al. HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments. Ann Rheum Dis 1998;57:209-13.
24. van der Horst-Bruinsma I, Visser H, Hazes JM, Breedveld FC, Verduyn W, Schreuder GM, et al. HLA-DQ-associated predisposition to and dominant HLA-DR-associated protection against rheumatoid arthritis. Hum Immunol 1999;60:152-8.
25. Winchester R, Dwyer E, Rose S. The genetic basis of rheumatoid arthritis. The shared epitope hypothesis. Rheum Dis Clin North Am 1992;18:761-83.
26. Hulsmans HM, Jacobs JW, van der Heijde DM, Albada-Kuipers GA, Schenk Y, Bijlsma JW. The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum 2000;43:1927-40.
27. Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum 1998;41:1571-82.
28. Zanelli E, Breedveld FC, De Vries RR. HLA class II association with rheumatoid arthritis: facts and interpretations. Hum Immunol 2000;61:1254-61.
29. Peltomaa R, Paimela L, Helve T, Leirisalo-Repo M. Effect of treatment on the outcome of very early rheumatoid arthritis. Scand J Rheumatol 2001;30:143-8.
30. Calguneri M, Pay S, Caliskaner Z, Apras S, Kiraz S, Ertenli I, et al. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol 1999;17:699-704.
31. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpelo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
32. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
33. Strand V, Sharp JT. Radiographic data from recent randomized controlled trials in rheumatoid arthritis: what have we learned? Arthritis Rheum 2003;48:21-34.